# About Thymosin Alpha-1 Review — thymosin alpha 1 Editorial Project

> About thymosin alpha 1 Review: an independent editorial project summarizing the peer-reviewed research literature on thymosin alpha-1. Not a clinic. Not a vendor.

## About This Site

Thymosin Alpha-1 Review is an independent editorial project that publishes summaries of the peer-reviewed research literature on thymosin alpha 1. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The name of this project — and the domain rxthymosinalpha1.com — reflects the position we occupy relative to the research literature: a systematic reading of published clinical evidence, organized to be accessible to researchers, clinicians, and informed members of the public. The 'rx' in the domain is a reference to the prescription-status history of thymalfasin in approved markets, not a claim that this site provides prescriptions, fills orders, or offers clinical services. It does none of those things.

thymosin alpha 1 is a 28-amino-acid peptide with a substantial published clinical trial record spanning hepatitis B and C (the primary approved indications in 35+ countries), sepsis, HIV immune reconstitution, oncology adjuvant therapy, COVID-19 immune dysregulation, and aging-associated immune decline. The literature is large, internally contested in some areas (the sepsis mortality data in particular), and growing.

This site does not take positions on whether thymosin alpha 1 should be used for any particular purpose. It summarizes what controlled trials have found, notes where evidence is strong and where it is weak, and cites every quantitative claim to its primary source. Readers who encounter references to Zadaxin, thymalfasin, Tα1, or TA-1 across this site are reading about the same molecule under different names.

We draw entirely from the published peer-reviewed literature. We do not cite community forum reports as evidence of efficacy. We do not reproduce manufacturer marketing claims. We do not manufacture, sell, or distribute thymosin alpha 1 or any related product. We have no commercial relationship with any producer, distributor, compounding pharmacy, or clinical service.

For citations and primary sources, visit the [references](/references) page. For questions about dosing protocols in the clinical literature, visit the [thymosin alpha-1 dosage](/dosage) page. The [frequently asked questions](/faq) page addresses the most common reader queries from the research and community record.

---

The thymosin alpha-1 research record — hepatitis trials, sepsis RCTs, immune reconstitution data — read at the source and indexed here, held by no clinic and sold by no one.